My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.21 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Unusual volume stocks in Tuesday's session ↗

Today 13:00 EST

Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

December 19, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Discover the most active stocks in Friday's session. ↗

December 19, 2025

Let's have a look at what is happening on the US markets on Friday. Below you can find the most active stocks in today's session.

Via Chartmill

Which stocks are moving on Friday? ↗

December 19, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Via Chartmill

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal ↗

December 19, 2025

Via Stocktwits

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Which stocks are gapping on Friday? ↗

December 19, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Discover the top movers in Friday's pre-market session. ↗

December 19, 2025

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Amicus Therapeutics Earnings Preview ↗

April 30, 2025

Via Benzinga

Earnings Scheduled For February 19, 2025 ↗

February 19, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts ↗

January 13, 2025

Via Benzinga

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Via The Motley Fool

Topics Regulatory Compliance

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Amicus Therapeutics Inc (NASDAQ:FOLD) Q3 2025 Earnings: A Landmark Quarter with Strong Profitability Beat ↗

November 04, 2025

Amicus Therapeutics (FOLD) beats Q3 2025 earnings estimates with strong revenue growth and a major milestone in profitability, driving positive market momentum.

Via Chartmill

This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

September 18, 2025

Via Benzinga

A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics ↗

November 12, 2024

Via Benzinga

The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts ↗

November 12, 2024

Via Benzinga

Amicus (FOLD) Q2 Revenue Jumps 22% ↗

August 01, 2025

Via The Motley Fool

Topics Intellectual Property

Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading ↗

July 31, 2025

Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 01, 2025

Via Benzinga

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? ↗

December 13, 2024

Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.

Via Benzinga

Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) ↗

November 12, 2024

Via Benzinga

Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights ↗

November 07, 2024

Via Benzinga

Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts ↗

October 11, 2024

Via Benzinga

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug ↗

October 17, 2024

Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA...

Via Benzinga

Topics Intellectual Property Lawsuit

Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday ↗

October 17, 2024

Via Benzinga

FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.